The TIME program enabled activation of a new clinical trial site within 4 business days for a PARPi study. Read on to learn how the patient was able to dose within 10 days of being identified as a match for the trial.
Listen to industry leaders discuss longitudinal endpoints for disease progression, the evolving role of liquid biopsy within drug development, and the value of methylation in combination with liquid biopsy.
Watch replay
The traditional model of activating clinical trials is widely acknowledged as inefficient. The process of establishing a clinical site, negotiating partnerships between sites and sponsors, then attempting to recruit eligible patients in nearby areas can take many months, and it becomes a burden to trial site staff, sponsors, and patients.
Read more
Mike Yasiejko, General Manager and Executive Vice President at Tempus, recently spoke with Andrew Mazar, PhD, Chief Operating Officer at Actuate Therapeutics, about the ways Tempus’ liquid biopsy (xF+) and methylation assays have been valuable to Actuate’s work and how the company has benefitted from the partnership
Read more
